随着靶向药物的批准,急性髓细胞性白血病(AML)的治疗前景发生了巨大变化,包括维尼托克,Midostaurin,gilteritinib,ivosidenib,和Enasidenib,在其他人中。然而,老年AML患者的结局仍然较差,因此仍需要更有效,毒性更小的治疗方案.这篇综述探讨了新型治疗方法和有希望的组合方法的疗效,以进一步改善AML患者的治疗结果。
The therapeutic landscape for acute myeloid leukemia (AML) has changed dramatically with the approval of targeted agents, including venetoclax, midostaurin, gilteritinib, ivosidenib, and enasidenib, among others. However, older patients with AML continue to experience poorer outcomes and are in ongoing need of more effective and less toxic regimens. This review examines the efficacy of novel therapeutics and promising combination approaches to further improve outcomes in the treatment of patients with AML.